Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 100
- Registration Number
- NCT05533632
- Locations
- 🇨🇱
Hospital San Juan de Dios_Santiago, Región Metropolitana, Santiago, Región Metropolitana, Chile
🇨🇱Hospital Padre Hurtado, Santiago, Región Metropolitana, Chile
🇨🇱Servicios Médicos Godoy Limitada, Santiago, Región Metropolitana, Chile
A Research Study of a New Medicine NNC0113-6856 in Healthy Males
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT05521256
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 568
- Registration Number
- NCT05514535
- Locations
- 🇺🇸
Valley Research, Fresno, California, United States
🇺🇸First Valley Medical Group, Lancaster, California, United States
🇺🇸Loma Linda Univ Hlth Cr Endo, Loma Linda, California, United States
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1139
- Registration Number
- NCT05503927
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 388
- Registration Number
- NCT05502562
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05498610
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 245
- Registration Number
- NCT05486065
- Locations
- 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Velocity Clin Res Gardena, Gardena, California, United States
🇺🇸First Valley Med Grp Lancaster, Lancaster, California, United States
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05479591
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 388
- Registration Number
- NCT05478252
- Locations
- 🇿🇦
Precise Clinical Solutions (Pty) Ltd, Durban, KwaZulu-Natal, South Africa
🇿🇦Dr Pillay's Rooms, Durban, KwaZulu-Natal, South Africa
🇵🇱PANSTWOWY INSTYTUT MEDYCZNY MSWiA, Warszawa, Poland
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05473286